Pfizer’s recent acquisition of Wyeth took place at human-health level, but both companies happened to have animal-health divisions.
So, when Pfizer Animal Health acquired products from Ft. Dodge Animal Health (via Wyeth), it created an opportunity to fill in some gaps and strengthen services, Pfizer executives told Dairy Herd Management on Monday.
The executives reiterated that it was a human-health-driven event, but the benefits that will accrue to the animal-health side are synergistic and even serendipitous. “We are fortunate to be able to take advantage of it,” says Clint Lewis, president of Pfizer Animal Health.
Many of the larger animal-health companies are subsidiaries of larger human-health companies, Lewis points out. And, it’s no secret that the human-health companies are facing tremendous challenges because many of their blockbuster products are going off patent and into the generic market. So, these mergers and acquisitions shed light on what else the companies have, including some dynamic animal-health divisions.
Pfizer Animal Health will inherit a product from Ft. Dodge known as Factrel; it is a GnRH product used for the treatment of cystic ovary disease. Pfizer did not have a GnRH product prior to bringing Factrel on board, so it rounds out the company’s reproductive-management portfolio, along with Lutalyze Sterile Solution and CIDR cattle inserts (progesterone), according to Mike Layfield, senior director of dairy operations.
Then, there is the people element. The acquisition will allow us to bring in “some of the best talent in the industry,” Lewis said.
“Some of the individuals from Ft. Dodge will move to a different company, and we’re looking to keep as many colleagues from Ft. Dodge as possible,” he added.
The transition of new products from Ft. Dodge to Pfizer Animal Health took place seamlessly, the executives emphasized. “We worked tirelessly behind the scenes to make sure there was no interruption in product flow,” they said.
Not all of Ft. Dodge’s products went to Pfizer, however. Many of them went to another company, Boehringer Ingelheim. To read about that, click here.